Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASKi-1: Fostamatinib in RA patients on MTX
NCT00326339Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Aug 2006
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of fostamatinib in rheumatoid arthritis (RA), sponsored by Rigel Pharmaceuticals, Inc.. Started Aug 2006; status: completed.
02
Drugs
fostamatinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00326339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326339.